Journal of Clinical Medicine (Oct 2021)

The Role of Uric Acid in Acute and Chronic Coronary Syndromes

  • Alessandro Maloberti,
  • Marco Biolcati,
  • Giacomo Ruzzenenti,
  • Valentina Giani,
  • Filippo Leidi,
  • Massimiliano Monticelli,
  • Michela Algeri,
  • Sara Scarpellini,
  • Stefano Nava,
  • Francesco Soriano,
  • Jacopo Oreglia,
  • Alice Sacco,
  • Nuccia Morici,
  • Fabrizio Oliva,
  • Federica Piani,
  • Claudio Borghi,
  • Cristina Giannattasio

DOI
https://doi.org/10.3390/jcm10204750
Journal volume & issue
Vol. 10, no. 20
p. 4750

Abstract

Read online

Uric acid (UA) is the final product of the catabolism of endogenous and exogenous purine nucleotides. While its association with articular gout and kidney disease has been known for a long time, new data have demonstrated that UA is also related to cardiovascular (CV) diseases. UA has been identified as a significant determinant of many different outcomes, such as all-cause and CV mortality, and also of CV events (mainly Acute Coronary Syndromes (ACS) and even strokes). Furthermore, UA has been related to the development of Heart Failure, and to a higher mortality in decompensated patients, as well as to the onset of atrial fibrillation. After a brief introduction on the general role of UA in CV disorders, this review will be focused on UA’s relationship with CV outcomes, as well as on the specific features of patients with ACS and Chronic Coronary Syndrome. Finally, two issues which remain open will be discussed: the first is about the identification of a CV UA cut-off value, while the second concerns the possibility that the pharmacological reduction of UA is able to lower the incidence of CV events.

Keywords